Alopecia Associated with Fluconazole Therapy

1 September 1995 | Volume 123 Issue 5 | Pages 354-357

Objective: To describe the association between fluconazole and reversible alopecia.

Design: A retrospective survey of 1) patients enrolled in NIAID Mycoses Study Group [MSG] protocols involving the long-term use of fluconazole for treatment of endemic mycoses and 2) patients treated with fluconazole outside of a protocol setting but by the MSG investigators who were MSG members.

Setting: 26 MSG sites in the United States.

Patients: 33 patients with various deep and superficial mycoses who developed alopecia while receiving fluconazole.

Results: 11 of 26 investigators reported a total of 33 patients with substantial alopecia related to fluconazole therapy. Underlying mycoses included blastomycosis, sporotrichosis, histoplasmosis, cryptococcosis, coccidioidomycosis, and mucosal candidiasis. In separate MSG studies, 17 of 136 (12.5%) and 8 of 40 (20%) patients had substantial reversible alopecia associated with fluconazole therapy. Eight patients who were not in the protocol had similar adverse effects. Twenty-nine of 33 patients (88%) received at least 400 mg of fluconazole daily for a mean of 7. 1 months. Alopecia developed a median of 3 months after initiation of fluconazole therapy and involved the scalp in all patients. Other sites were involved in about one third of patients. Three patients required wigs because of extensive hair loss. Alopecia resolved within 6 months of discontinuation of fluconazole therapy or reduction of the daily dose by at least 50%.

Conclusions: Alopecia appears to be a common adverse event associated with higher-dose (400 mg/d) fluconazole given for 2 months or longer. This effect may be severe but is reversed by discontinuing fluconazole therapy or substantially reducing the daily dose.

Author and Article Information

From the University of Alabama at Birmingham, Birmingham, Alabama; University of Michigan, Ann Arbor, Michigan; Duke University Medical Center, Durham, North Carolina; University of Texas Medical Center and Baylor College of Medicine, Houston, Texas; Research Medical Center and University of Missouri, Kansas City, Missouri; University of Texas at San Antonio Medical Center, San Antonio, Texas; University of Mississippi, Jackson, Mississippi; and Wayne State Medical School, Detroit, Michigan.
Acknowledgments: The authors thank Richard M. Cadle, PharmD, Baylor College of Medicine and Veterans Administration Medical Center, Houston, Texas; Mary Ellen Bradley, RN, University of Alabama at Birmingham, Birmingham, Alabama; Heidi Gutsch, MSN, RN, University of Michigan and Veterans Administration Medical Center, Ann Arbor, Michigan; and Carmelita V. Tuazan, MD, George Washington University Medical Center, Washington, DC, for their participation, and Ms. Windell Ross for assistance in manuscript preparation.
Grant Support: In part by a grant from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, contract NO1-AI-15082.
Requests for Reprints: Peter G. Pappas, MD, Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, 1900 University Boulevard, 229 Tinsley Harrison Tower, Birmingham, AL 35294.
Current Author Addresses: Dr. Pappas: Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, 1900 University Boulevard, 229 Tinsley Harrison Tower, Birmingham, AL 35294.